Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2275)	11/16/2004 11:05:41 PM
From: PCSS	Read Replies (1) of 3044

G-S RESEARCH TONITE At its R&D day yesterday, MLNM discussed a growing pipeline that has benefited from renewed focus and a broad platform of technologies to improve productivity. We expect 8 products drug candidates to be in clinical trials for inflammation, cancer and cardiovascular diseases in 2005. Management also reiterated the goal of breaking even in 2006. We believe sustainable growth beyond 2006 will depend on expansion of indications for Velcade & Integrilin, approval of some of the current drug candidates and continued cost control. Despite the broad platform and growing pipeline, we maintain our In-Line rating while awaiting for Phase II data on the next wave of candidates. Risks are slower sales, failure in development and higher expenses. Our coverage view is Neutral.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next